Apoptosis-mimicking synthetic entities and use thereof in medical treatment
AssigneeVasogen Ireland Limited
InventorsAnthony E. Bolton, Arkady Mandel
Life of this patent
Estimating the term…
Loading patent…
AssigneeVasogen Ireland Limited
InventorsAnthony E. Bolton, Arkady Mandel
Estimating the term…
Synthetic and semisythetic bodies having a three-dimensional structure, sized and shaped to resemble apoptotic cells and apoptotic bodies, and having phosphatidyl serine (PS) molecules on the surface thereof, are administered to a patient, to alleviate a variety of disorders such as T-cell mediated disorders (autoimmune conditions). The bodies are believed to trigger and apoptosis-like mechanism in the patient.
A unit dosage form comprising a pharmaceutically acceptable carrier and synthetic or semi-synthetic phosphatidylserine (PS)-carrying bodies in an amount from about 500 to about 500,000,000 per unit of administration.
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols: one of the hydroxy compounds having nitrogen atoms, e.g.…
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: intimate…
Term ended 18 Sep 2021 (estimated)
This invention relates to synthetic and semi-synthetic compositions having biochemical activity, and to the uses thereof in the treatment and/or prophylaxis of various disorders in mammalian patients. More particularly, it relates to preparation and use of synthetic and semi-synthetic bodies which can mimic the process of cell apoptosis after introduction into the body of a patient, to produce beneficial effects.
The following documents are cited herein:
1. Kerr, J. F. R., Wyllie A. H., Currie, A. R. (1992), “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.” British Journal of Cancer 26: 239-257;
FIG. 1 shows net ear swelling (microns) in control and treated mice using the murine contact hypersensitivity (CHS) model.
FIG. 2 shows net ear swelling in control and treated mice in the CHS model where mice were treated with PS liposomes where the amount of PS in the liposome was varied.
FIG. 3 shows the change in ear swelling in control and treated mice where mice were treated with varying numbers of liposomes using the CHS model.
According to the present invention, synthetic and semi-synthetic bodies which have the property of mimicking in vivo apoptotic cells and/or apoptotic bodies in that they are taken up by cells of the patient's immune system with accompanying beneficial effects such as inhibition of pro-inflammatory cytokines in vivo and/or promotion of anti-inflammatory cytokines are administered to patients. These synthetic and semi-synthetic bodies are three dimensional bodies having shapes and dimensions ranging from those resembling mammalian cells to shapes and dimensions approximating to apoptotic bodies produced by apoptosis of mammalian cells (typically but not exclusively spheroidal, cylindrical, ellipsoidal including oblate and prolate spheroidal, serpentine, reniform, etc., and from about 50 nanometers to about 500 microns in diameter), and having phosphatidyl serine (PS) molecules on the surface thereof. Such bodies are hereinafter referred to as “PS-carrying bodies”.
The term “synthetic or semi-synthetic PS-carrying bodies” refers to liposomes containing PS as well as up to 50% non-PS components of the liposomes. The term “non-liposomal synthetic bodies” refers PS-carrying bodies that are not liposomes.
As noted above, exposed PS on the membrane of a cell is known to play a key role in the clearance of apoptotic lymphocytes by macrophages. A receptor for PS is present on macrophages. A “phosphatidylserine receptor” or “PS receptor” is a receptor on an antigen presenting cell (APC), such as a macrophage, whose activity is blocked by soluble phosphatidylserine, either monomeric or oligomeric. It is contemplated that the PS receptor may also be present on other APCs, such as dendritic cells and B cells. It is understood that PS is a ligand of the PS receptor.